A phase 1b study for fuzuoparib (PARP inhibitor) in combination with Albumin Palitaxel and Camrelizumab (PD-1 inhibitor) in the treatment of patients with advanced solid cancer
Latest Information Update: 05 Feb 2020
At a glance
- Drugs Camrelizumab (Primary) ; Fuzuloparib (Primary) ; Paclitaxel (Primary)
- Indications Cholangiocarcinoma; Non-small cell lung cancer; Small cell lung cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions
Most Recent Events
- 05 Feb 2020 New trial record